Torsdag 11 Juni | 17:33:06 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-11-03 07:00 Kvartalsrapport 2026-Q3
2026-08-18 07:00 Kvartalsrapport 2026-Q2
2026-06-10 - X-dag ordinarie utdelning OSSD 0.00 SEK
2026-06-09 - Årsstämma
2026-05-05 - Kvartalsrapport 2026-Q1
2026-02-03 - Bokslutskommuniké 2025
2025-11-04 - Kvartalsrapport 2025-Q3
2025-08-19 - Kvartalsrapport 2025-Q2
2025-06-12 - X-dag ordinarie utdelning OSSD 0.00 SEK
2025-06-11 - Årsstämma
2025-05-06 - Kvartalsrapport 2025-Q1
2025-02-04 - Bokslutskommuniké 2024
2024-12-18 - Extra Bolagsstämma 2024
2024-11-12 - Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-05-22 - X-dag ordinarie utdelning OSSD 0.00 SEK
2024-05-21 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-06 - Bokslutskommuniké 2023
2023-11-21 - Kvartalsrapport 2023-Q3
2023-10-16 - Extra Bolagsstämma 2023
2023-08-22 - Kvartalsrapport 2023-Q2
2023-06-01 - X-dag ordinarie utdelning OSSD 0.00 SEK
2023-05-31 - Årsstämma
2023-05-23 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning OSSD 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-02-22 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-20 - X-dag ordinarie utdelning OSSD 0.00 SEK
2021-05-19 - Årsstämma
2021-05-12 - Kvartalsrapport 2021-Q1
2021-04-09 - Extra Bolagsstämma 2021
2021-02-11 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-08-19 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning OSSD 0.00 SEK
2020-05-20 - Årsstämma
2020-05-13 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
OssDsign är en utvecklare och leverantör av ortobiologiska produkter. Bolaget utvecklar och marknadsför produkter som stödjer kroppens egen läkningsförmåga, exempelvis OssDsign Catalyst, som är ett nanosyntetiskt bentransplantat för dubbla benbildningsvägar genom fusionsmassa. Bolaget erbjuder sina produkter runtom den globala marknaden. OssDsign grundades 2011 och har sitt huvudkontor i Uppsala.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-06-10 10:55:47

On 9 June 2026, OssDsign AB (publ) held its annual general meeting for 2026. Below is a summary of the resolutions passed at the annual general meeting (complete information and documents regarding the decisions of the meeting are available on the company's website www.ossdsign.com).

The annual general meeting resolved:

  • to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2025;
  • that the company's result shall be carried forward in new account and that no dividend shall be paid for the financial year 2025;
  • to grant the board members and the CEO discharge from liability for the financial year 2025;
  • that the board of directors shall consist of five ordinary members without deputy members, to re-elect Christer Fåhraeus, Jill Schiaparelli, David Jern and Tomas Blomquist as ordinary board members, election of Per Aniansson as new ordinary board member, and to elect Per Aniansson as new chairman of the board;
  • that a registered accounting firm shall be elected as auditor and to re-elect Ernst & Young AB as the company's auditor;
  • that fees payable to the board members until the end of the next annual general meeting shall amount to a total of SEK 1,300,000 out of which SEK 400,000 shall be paid to the chairman and SEK 300,000 to each of the other board members except for Christer Fåhraeus to whom no board fee is to be paid. In addition, it was resolved that fees shall be paid to the board members serving on the audit committee for the period until the end of the next annual general meeting in a total amount of SEK 120,000, of which SEK 80,000 shall be paid to the chairman of the audit committee and SEK 40,000 to the other member of the audit committee;
  • that the auditor is to be paid in accordance with approved invoices;
  • on an authorization for the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures through which the company's share capital may be increased by an amount corresponding to not more than twelve (12) per cent of the share capital after such issue(s);
  • to adopt the board's proposed resolution on (i) implementation of a long-term incentive program for employees and contractors (Warrant Programme 2026/2029:1) through a directed issue of no more than 3,100,000 warrants of series 2026/2029:1 to the company and/or any of its subsidiaries and approval of the subsequent transfer of the issued warrants to certain employees and contractors within the group against payment of the market value of the option right or, provided that it does not entail negative tax consequences for the group, free-of-charge, and (ii) cancellation of Warrant Programme 2025/2028:1 which has not been utilised. Each warrant entitles the holder to subscribe for one (1) new share in the company, as adjusted downwards by application of the mandatory so-called quotient exercise model set forth in the proposed resolution, during the period from and including 1 July 2029 until and including 31 December 2029, against payment of a subscription price per new share corresponding to 160 percent of the volume weighted average trading price for the company's share on Nasdaq First North Growth Market during a period of five (5) trading days before the annual general meeting. The warrants are governed by customary terms and conditions, including any adjustments to the subscription price and the number of new shares that each warrant entitles the holder to subscribe for in the event of certain events affecting the company.